Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sctbio A S focuses on the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This action is handled by 1 distinct examiner and is located in 1 distinct art unit. This suggests a targeted intellectual property strategy within the pharmaceutical sector.
JUEDES, AMY E is the busiest examiner for this portfolio. This examiner is currently managing 1 pending office action. With 1 distinct examiner and 1 pending office action total, the workload is entirely concentrated. This suggests a focused prosecution strategy within a single art unit. For the company, having 1 distinct examiner means that the outcome of its current pending matter is subject to a single individual's review. This centralized profile, featuring 1 pending office action and 1 distinct art unit, indicates that the company's immediate patent office activity is limited to a specific technical area. Practitioners can focus their efforts on a single point of contact for all current pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JUEDES, AMY E | 1 | 44.8% | +41.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18277041 | PATIENT SELECTION FOR TREATMENT WITH DENDRITIC CELL VACCINATION | JUEDES, AMY E | 30d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18277041 | PATIENT SELECTION FOR TREATMENT WITH DENDRITIC CELL VACCINATION | JUEDES, AMY E | 30d overdue |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18277041 | PATIENT SELECTION FOR TREATMENT WITH DENDRITIC CELL VACCINATION | JUEDES, AMY E | 1644 | §101§102§112Other | Non-Final OA | 30d overdue | Pending | Aug 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial